Madge K.  Shafmaster net worth and biography

Madge Shafmaster Biography and Net Worth

Maggie has almost 30 years of experience providing intellectual property advice to the biotechnology and pharmaceutical industries.  She holds a B.A. in Biology from University of California, a Ph.D. in Molecular Biology and Virology from Cornell University Graduate School of Medical Sciences and a J.D. summa cum laude from New York Law School.  After spending 8 years at the boutique IP firm of Fish & Neave in New York, Maggie spent 14 years at Genzyme, where she ultimately became Sr. Vice President and Chief Patent Counsel.  In that role, she was responsible for providing strategic guidance and IP advice for major commercial and research transactions as well as for developing and implementing strategies to procure, license, defend and enforce Genzyme’s worldwide intellectual property.  Upon Genzyme’s acquisition by Sanofi, Maggie became Vice President and Chief Patent Counsel at Sanofi Pasteur, where she was responsible for leading IP attorneys and agents in the U.S., Canada, France and India.   In 2014, Maggie became an independent IP consultant, providing strategic advice related to IP portfolio development, commercial transactions and potential and ongoing patent and trade secret disputes.

What is Madge K. Shafmaster's net worth?

The estimated net worth of Madge K. Shafmaster is at least $81.89 thousand as of September 23rd, 2024. Shafmaster owns 5,533 shares of Promis Neurosciences stock worth more than $81,888 as of August 25th. This net worth approximation does not reflect any other assets that Shafmaster may own. Learn More about Madge K. Shafmaster's net worth.

How do I contact Madge K. Shafmaster?

The corporate mailing address for Shafmaster and other Promis Neurosciences executives is 1920 Yonge Street Suite 200, Toronto A6, M4S 3E2. Promis Neurosciences can also be reached via phone at (416) 847-6898 and via email at [email protected]. Learn More on Madge K. Shafmaster's contact information.

Has Madge K. Shafmaster been buying or selling shares of Promis Neurosciences?

Madge K. Shafmaster has not been actively trading shares of Promis Neurosciences over the course of the past ninety days. Most recently, on Monday, September 23rd, Madge K. Shafmaster bought 2,800 shares of Promis Neurosciences stock. The stock was acquired at an average cost of $32.00 per share, with a total value of $89,600.00. Following the completion of the transaction, the director now directly owns 5,533 shares of the company's stock, valued at $177,056. Learn More on Madge K. Shafmaster's trading history.

Who are Promis Neurosciences' active insiders?

Promis Neurosciences' insider roster includes Neil Cashman (Chief Scientific Officer and Co-founder), Johanne Kaplan (Insider), Johanne Kaplan (Chief Development Officer), Madge Shafmaster (Director), and Eugene Williams (Chairman and Co-Founder). Learn More on Promis Neurosciences' active insiders.

Are insiders buying or selling shares of Promis Neurosciences?

In the last twelve months, Promis Neurosciences insiders bought shares 6 times. They purchased a total of 710,585 shares worth more than $8,655,727.23. The most recent insider tranaction occured on April, 22nd when Director Patrick D Kirwin bought 4,000 shares worth more than $45,320.00. Insiders at Promis Neurosciences own 1.5% of the company. Learn More about insider trades at Promis Neurosciences.

Information on this page was last updated on 4/22/2026.

Madge K. Shafmaster Insider Trading History at Promis Neurosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/23/2024Buy2,800$32.00$89,600.005,533View SEC Filing Icon  
9/20/2024Buy2,400$31.25$75,000.002,733View SEC Filing Icon  
See Full Table

Madge K. Shafmaster Buying and Selling Activity at Promis Neurosciences

This chart shows Madge K Shafmaster's buying and selling at Promis Neurosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Promis Neurosciences Company Overview

Promis Neurosciences logo
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $15.36
Low: $14.50
High: $15.36

50 Day Range

MA: $13.31
Low: $10.16
High: $15.19

2 Week Range

Now: $15.36
Low: $6.27
High: $27.40

Volume

60,642 shs

Average Volume

106,621 shs

Market Capitalization

$137.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A